We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

177 hedge funds and large institutions have $396M invested in Vanda Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 67 increasing their positions, 61 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

4.5% more ownership

Funds ownership: 98.05% → 102.55% (+4.5%)

10% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 61

2% more capital invested

Capital invested by funds: $389M → $396M (+$6.97M)

7% less funds holding

Funds holding: 190 → 177 (-13)

38% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 32

48% less call options, than puts

Call options by funds: $17K | Put options by funds: $33K

Holders
177
Holders Change
-13
Holders Change %
-6.84%
% of All Funds
2.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
67
Reduced
61
Closed
32
Calls
$17K
Puts
$33K
Net Calls
-$16K
Net Calls Change
+$50K

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$9.46M
2
State Street
State Street
Massachusetts
+$5.79M
3
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$5.35M
4
Allspring Global Investments
Allspring Global Investments
North Carolina
+$3.98M
5
Citadel Advisors
Citadel Advisors
Florida
+$3.3M

Top Sellers

Rank Fund Capital Flow
1
Macquarie Group
Macquarie Group
Australia
-$9.78M
2
EIP
Epoch Investment Partners
New York
-$4.86M
3
PAI
Palo Alto Investors
California
-$4.25M
4
Pacer Advisors
Pacer Advisors
Pennsylvania
-$2.32M
5
CSS
Cubist Systematic Strategies
Connecticut
-$2.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$4.03M +$148K +21,073 +4%
Two Sigma Advisers
27
Two Sigma Advisers
New York
$3.92M +$872K +124,000 +27%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$3.47M +$38K +5,402 +1%
Two Sigma Investments
29
Two Sigma Investments
New York
$3.45M +$435K +61,885 +14%
PAI
30
Palo Alto Investors
California
$3.28M -$4.25M -604,910 -56%
Invesco
31
Invesco
Georgia
$2.5M +$67.5K +9,594 +3%
KAM
32
Krensavage Asset Management
New York
$2.46M +$114K +16,270 +5%
Principal Financial Group
33
Principal Financial Group
Iowa
$2.38M -$34.5K -4,907 -1%
PIM
34
Profit Investment Management
Maryland
$2.26M -$14.7K -2,091 -0.6%
Walleye Capital
35
Walleye Capital
New York
$2.14M +$1.18M +168,329 +114%
Los Angeles Capital Management
36
Los Angeles Capital Management
California
$1.62M +$1.19M +169,768 +248%
Victory Capital Management
37
Victory Capital Management
Texas
$1.6M -$305K -43,409 -16%
Rafferty Asset Management
38
Rafferty Asset Management
New York
$1.56M +$632K +89,946 +64%
Connor, Clark & Lunn Investment Management (CC&L)
39
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.52M +$37.6K +5,342 +2%
Citigroup
40
Citigroup
New York
$1.51M +$800K +113,816 +105%
JP Morgan Chase
41
JP Morgan Chase
New York
$1.41M -$94.3K -13,412 -6%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$1.31M +$59.7K +8,485 +5%
SEI Investments
43
SEI Investments
Pennsylvania
$1.29M -$22.2K -3,163 -2%
PAM
44
Panagora Asset Management
Massachusetts
$1.25M -$768K -109,298 -37%
Franklin Resources
45
Franklin Resources
California
$1.11M +$5.91K +840 +0.5%
BNP Paribas Financial Markets
46
BNP Paribas Financial Markets
France
$1.1M +$637K +90,573 +127%
Norges Bank
47
Norges Bank
Norway
$1.08M – – –
HSA
48
Hussman Strategic Advisors
Maryland
$1.06M – – –
CANY
49
Caxton Associates (New York)
New York
$1.04M +$167K +23,759 +18%
Massachusetts Financial Services
50
Massachusetts Financial Services
Massachusetts
$1.02M -$29.8K -4,234 -3%
1
2
3 4 5

VNDA Hedge Fund Activity: Q1 2023 in Review

177 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2023, worth a combined $396M — up 1.8% from $389M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of VNDA and 20 opened new positions — a net loss of 12 holders — while 61 trimmed existing stakes and 67 added.

The largest buyer was Bank of America, adding an estimated $9.46M. The largest seller was Macquarie Group, exiting entirely with an estimated $9.78M sold.

  • 177 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2023, down from 190 in Q4 2022.
  • Funds reported $396M of Vanda Pharmaceuticals stock for Q1 2023, up 1.8% quarter-over-quarter.
  • 20 funds opened new Vanda Pharmaceuticals positions in Q1 2023 and 32 closed out, a net change of -12 holders.
  • The largest Vanda Pharmaceuticals buyer in Q1 2023 was Bank of America, an estimated $9.46M added.
  • The largest Vanda Pharmaceuticals seller in Q1 2023 was Macquarie Group, an estimated $9.78M sold.

Based on aggregated 13F filings for Q1 2023.